Cargando…
Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial
IMPORTANCE: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, 1.25%, designed for managing presbyopia and enhanced with a proprietary vehicle. OBJECTIVE: To evaluate the efficacy and safety of pilocarpine hydrochloride, 1.25%, in individuals w...
Autores principales: | Waring, George O., Price, Francis W., Wirta, David, McCabe, Cathleen, Moshirfar, Majid, Guo, Qiang, Gore, Anu, Liu, Haixia, Safyan, Eleonora, Robinson, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895317/ https://www.ncbi.nlm.nih.gov/pubmed/35238902 http://dx.doi.org/10.1001/jamaophthalmol.2022.0059 |
Ejemplares similares
-
Combinations of Pilocarpine and Oxymetazoline for the Pharmacological Treatment of Presbyopia: Two Randomized Phase 2 Studies
por: Price, Francis W., et al.
Publicado: (2021) -
Corneal Refractive Procedures for the Treatment of Presbyopia
por: Moussa, Kareem, et al.
Publicado: (2017) -
Agnes
por: Stamm, Peter, 1963- -
Agnes Grey /
por: Brontë, Anne, 1820-1849
Publicado: (1997) -
In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment
por: Jackson, Mitchell A., et al.
Publicado: (2022)